At present, the recombinant vaccine clinical and industrialization base construction project of Health Guard (Kunming) Biotechnology Co., Ltd. obtained the "Drug Production License" issued by the Medical Products Administration of Yunnan Province.

Health-Guard (Kunming) Biotechnology Co., Ltd. is a wholly-owned subsidiary of Beijing Health Guard Biotechnology Co., Ltd. Its recombinant vaccine clinical and industrialization base construction project invested and constructed by Yunnan Dian Zhong New Area, covers an area of around 140 mu with a total investment of 1.195 billion yuan. The overall planned construction area of production equipment exceeds 80,000 square meters. Built according to the construction standards of China, Europe, and Wealth Health Organization GMP, the base includes production workshops for trivalent HPV vaccines and nine-valent HPV vaccines, a quality control building, a power workshop, and other related supporting facilities. The base is designed to produce 10 million doses of the trivalent HPV vaccine and 30 million doses of the nine-valent HPV vaccine annually. It integrates functions such as research and development, production, logistics, and office operations to meet the needs of innovative vaccine R&D implementation and industrialization development.

Health-Guard (Kunming) Biotechnology Co., Ltd. initiated the technology transfer for the trivalent HPV vaccine and the nine-valent HPV vaccine in February 2023 and May 2024, respectively; trial production began on August 1, 2023. Next, the company will accelerate the R&D process of developing products. The trivalent HPV vaccine is expected to be launched and available for sale in 2025, while the nine-valent HPV vaccine is expected to be launched in 2026.

Click here to view Chinese report

(Editors: Ines, Reena)